XTX Topco Ltd Acquires Shares of 83,286 Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

XTX Topco Ltd bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 83,286 shares of the company’s stock, valued at approximately $625,000. XTX Topco Ltd owned 0.19% of Kyverna Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Federated Hermes Inc. bought a new position in Kyverna Therapeutics during the 2nd quarter worth $120,000. Rhumbline Advisers bought a new position in shares of Kyverna Therapeutics in the second quarter worth $150,000. DekaBank Deutsche Girozentrale acquired a new position in Kyverna Therapeutics in the first quarter valued at about $181,000. Teachers Retirement System of The State of Kentucky bought a new stake in Kyverna Therapeutics during the first quarter worth about $313,000. Finally, Sofinnova Investments Inc. grew its stake in Kyverna Therapeutics by 378.5% during the second quarter. Sofinnova Investments Inc. now owns 47,850 shares of the company’s stock worth $359,000 after buying an additional 37,850 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Stock Down 8.5 %

Shares of Kyverna Therapeutics stock opened at $5.85 on Tuesday. The firm’s 50 day moving average is $7.82 and its 200 day moving average is $13.35. Kyverna Therapeutics, Inc. has a 1 year low of $5.72 and a 1 year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03. As a group, analysts predict that Kyverna Therapeutics, Inc. will post -3.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on KYTX. HC Wainwright reaffirmed a “neutral” rating and set a $7.00 price target on shares of Kyverna Therapeutics in a report on Thursday, September 19th. JPMorgan Chase & Co. cut their target price on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.40.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.